Evidence map›Paper›PMID 39112916›Full record

ArticleCurrent medical science2024

Anti-inflammatory and DNA Repair Effects of Astragaloside IV on PC12 Cells Damaged by Lipopolysaccharide.

Hai-Long Li, Li-Hua Shao, Xi Chen, Meng Wang, Qi-Jie Qin, Ya-Li Yang, Guang-Run Zhang, Yang Hai, Yi-Hong Tian

Abstract read
PubMed Publisher
In one paragraph

Article in Current medical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hai-Long Li *Department of Geriatrics, The Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou, 730000, China.
Li-Hua Shao *Key Laboratory for Mining, Innovation and Transformation of Traditional Chinese Medicine in Gansu Province and the New Product Creation Engineering Laboratory of Traditional Chinese Medicine in Gansu Province, Lanzhou, 730000, China.
Xi Chen *Key Laboratory for Mining, Innovation and Transformation of Traditional Chinese Medicine in Gansu Province and the New Product Creation Engineering Laboratory of Traditional Chinese Medicine in Gansu Province, Lanzhou, 730000, China.
Meng WangKey Laboratory for Mining, Innovation and Transformation of Traditional Chinese Medicine in Gansu Province and the New Product Creation Engineering Laboratory of Traditional Chinese Medicine in Gansu Province, Lanzhou, 730000, China.
Qi-Jie QinDepartment of Neurology, the First People's Hospital of Lanzhou, Lanzhou, Gansu, 730000, China.
Ya-Li YangKey Laboratory for Mining, Innovation and Transformation of Traditional Chinese Medicine in Gansu Province and the New Product Creation Engineering Laboratory of Traditional Chinese Medicine in Gansu Province, Lanzhou, 730000, China.
Guang-Run ZhangPeople's Hospital of Gansu Province, Lanzhou, 730000, China.
Yang HaiScientific Research and Experimental Center, Gansu University of Chinese Medicine, Lanzhou, 730000, China. cathyhaiyang@163.com.
Yi-Hong TianSchool of Public Health, Gansu University of Chinese Medicine, Lanzhou, 730000, China. tianyh0907@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to establish a neural cell injury model in vitro by stimulating PC12 cells with lipopolysaccharide (LPS) and to examine the effects of astragaloside IV on key targets using high-throughput sequence technology and bioinformatics analyses.

methodsPC12 cells in the logarithmic growth phase were treated with LPS at final concentrations of 0.25, 0.5, 0.75, 1, and 1.25 mg/mL for 24 h. Cell morphology was evaluated, and cell survival rates were calculated. A neurocyte inflammatory model was established with LPS treatment, which reached a 50% cell survival rate. PC12 cells were treated with 0.01, 0.1, 1, 10, or 100 µmol/L astragaloside IV for 24 h. The concentration of astragaloside IV that did not affect the cell survival rate was selected as the treatment group for subsequent experiments. NOS activity was detected by colorimetry; the expression levels of ERCC2, XRCC4, XRCC2, TNF-α, IL-1β, TLR4, NOS and COX-2 mRNA and protein were detected by RT-qPCR and Western blotting. The differentially expressed genes (DEGs) between the groups were screened using a second-generation sequence (fold change>2, P<0.05) with the following KEGG enrichment analysis, RT-qPCR and Western blotting were used to detect the mRNA and protein expression of DEGs related to the IL-17 pathway in different groups of PC12 cells.

resultsThe viability of PC12 cells was not altered by treatment with 0.01, 0.1, or 1 µmol/L astragaloside IV for 24 h (P>0.05). However, after treatment with 0.5, 0.75, 1, or 1.25 mg/mL LPS for 24 h, the viability steadily decreased (P<0.01). The mRNA and protein expression levels of ERCC2, XRCC4, XRCC2, TNF-α, IL-1β, TLR4, NOS, and COX-2 were significantly increased after PC12 cells were treated with 1 mg/mL LPS for 24 h (P<0.01); however, these changes were reversed when PC12 cells were pretreated with 0.01, 0.1, or 1 µmol/L astragaloside IV in PC12 cells and then treated with 1 mg/mL LPS for 24 h (P<0.05). Second-generation sequencing revealed that 1026 genes were upregulated, while 1287 genes were downregulated. The DEGs were associated with autophagy, TNF-α, interleukin-17, MAPK, P53, Toll-like receptor, and NOD-like receptor signaling pathways. Furthermore, PC12 cells treated with a 1 mg/mL LPS for 24 h exhibited increased mRNA and protein expression of CCL2, CCL11, CCL7, MMP3, and MMP10, which are associated with the IL-17 pathway. RT-qPCR and Western blotting analyses confirmed that the DEGs listed above corresponded to the sequence assay results.

conclusionLPS can damage PC12 cells and cause inflammatory reactions in nerve cells and DNA damage. astragaloside IV plays an anti-inflammatory and DNA damage protective role and inhibits the IL-17 signaling pathway to exert a neuroprotective effect in vitro.

Indexed as

Anti-Inflammatory AgentsCell SurvivalDNA RepairLipopolysaccharidesSaponinsTriterpenesAnimalsPC12 CellsRatsAnti-Inflammatory Agentsastragaloside ALipopolysaccharidesSaponinsTriterpenesastragaloside IVDNA damageinflammationPC12 cells

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.